CCL2 and neoplasm: Furthermore, CAR-Ts engineered to express the chemokine receptor CCR2b, which is the receptor of C-C motif chemokine ligand 2 (CCL2), have exhibited more than ten-fold enhanced migration towards CCL2-secreting tumor cells alongside amplified antitumor capacity in comparison with conventional CAR-Ts (90, 91).